Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731703 | 1.00 | SUCNR1 (0.50) | SUCNR1KDM4EALDH1A1LMNAPMP22 | |
| SCHEMBL28091824 | 0.81 | PPM1B (0.41) | SUCNR1ALDH1A1CYP1A2MEN1KMT2A | |
| SCHEMBL4733428 | 0.81 | PPM1B (0.41) | SUCNR1ALDH1A1CYP1A2MEN1KMT2A | |
| SCHEMBL28611363 | 0.80 | SUCNR1 (0.50) | SUCNR1KDM4EALDH1A1LMNAPMP22 | |
| SCHEMBL9306900 | 0.77 | SUCNR1 (0.36) | SUCNR1 | |
| SCHEMBL85522 | 0.76 | PPM1B (0.46) | ALDH1A1LMNATSHR | |
| SCHEMBL5719777 | 0.76 | PPM1B (0.46) | ALDH1A1LMNATSHR | |
| SCHEMBL16402657 | 0.76 | PPM1B (0.46) | ALDH1A1LMNATSHR | |
| SCHEMBL4639321 | 0.76 | — | — | |
| SCHEMBL27666533 | 0.75 | SUCNR1 (0.35) | SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12334502-B2 | Electrolytes for lithium-containing battery cells | APPLE INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250152518-A1 | PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2025-05-15 | — | — | US | disclosed |
| WO-2025064614-A1 | LIPID COMPOUNDS, LIPID NANOPARTICLES, AND PHARMACEUTICAL COMPOSITIONS | BROADPHARM INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-4499652-A1 | SYNTHETIC GLYCEROPHOSPHOLIPIDS COMPRISING AT LEAST ONE REACTIVE FUNCTION, PROCESS FOR PREPARING SAME AND USES THEREOF IN DIFFERENT APPLICATIONS | Universite de Rouen Normandie (FR) | 2025-02-05 | — | — | EP | disclosed |
| US-12151029-B2 | PEG lipids and uses thereof | MODERNATX, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| WO-2023180457-A1 | SYNTHETIC GLYCEROPHOSPHOLIPIDS COMPRISING AT LEAST ONE REACTIVE FUNCTION, PROCESS FOR PREPARING SAME AND USES THEREOF IN DIFFERENT APPLICATIONS | UNIVERSITE DE ROUEN-NORMANDIE (FR) | 2023-09-28 | — | — | WO | disclosed |
| US-9371485-B2 | Liquid crystal composition, liquid crystal element, and liquid crystal display device | Semiconductor Energy Laboraory Co., LTD. (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150210924-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, AND LIQUID CRYSTAL DISPLAY DEVICE | SEMICONDUCTOR ENERGY LAB (JP) | 2015-07-30 | — | — | US | disclosed |
| US-9039931-B2 | Liquid crystal composition, liquid crystal element, and liquid crystal display device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140117285-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, AND LIQUID CRYSTAL DISPLAY DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2014-05-01 | — | — | US | disclosed |
| CN-1038590-C | Process for preparing platinum complexes | SUNKYONG IND LTD (KR) | 1998-06-03 | — | — | CN | disclosed |
| EP-0501645-B1 | Smoking composition containing a tartrate salt flavorant-release additive | PHILIP MORRIS PROD (US) | 1997-01-15 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| US-5395947-A | Antitumor agents | SUNKYONG INDUSTRIES, LTD. (KR) | 1995-03-07 | — | — | US | disclosed |
| EP-0586378-A1 | NOVEL PLATINUM(II) COMPLEX AND PROCESSES FOR PREPARING THE SAME | SUNKYONG INDUSTRIES LTD. (KR) | 1994-03-16 | — | — | EP | disclosed |
| CN-1065274-A | Platinum complex and preparation method thereof | SUNKYONG IND LTD (KR) | 1992-10-14 | — | — | CN | disclosed |
| WO-1992016539-A1 | NOVEL PLATINUM(II) COMPLEX AND PROCESSES FOR PREPARING THE SAME | SUNKYONG INDUSTRIES LTD. (KR) | 1992-10-01 | — | — | WO | disclosed |
| EP-0501645-A1 | Smoking composition containing a tartrate salt flavorant-release additive | Philip Morris Products Inc. (US) | 1992-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152518-A1 | PEG LIPIDS AND USES THEREOF | LIPA, LIPG, LIPC | SUCNR1 3835/4885KDM4E 2572/4885ALDH1A1 1386/4885 |
| US-12151029-B2 | PEG lipids and uses thereof | LIPA, LIPG, LNPEP | SUCNR1 3934/4885KDM4E 2303/4885ALDH1A1 1384/4885 |
| US-12334502-B2 | Electrolytes for lithium-containing battery cells | CEL, CA3, SLC9B2 | SUCNR1 4583/4885KDM4E 1996/4885ALDH1A1 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.